Why the study?
Existing tools like the ARISCAT score perform well in general surgery, but no reliable classification instrument exists for predicting postoperative pulmonary complications in thoracic surgery.
Does a novel nomogram accurately predict 30-day postoperative pulmonary complications in older patients undergoing noncardiac thoracic surgery compared to existing risk scores?
Does a novel nomogram accurately predict 30-day postoperative pulmonary complications in older patients undergoing noncardiac thoracic surgery compared to existing risk scores?
A novel 8-variable nomogram accurately predicts 30-day postoperative pulmonary complications in older patients undergoing noncardiac thoracic surgery, demonstrating superior discrimination and net benefit compared to the ARISCAT and LAS VEGAS scores.
Answers are grounded in this paper and cite their sources.
Nomogram may aid PPC risk estimation after NCTS in older adults; leaves open external validation before clinical use.
BACKGROUND: The ARISCAT score, a prospectively developed generic classification for postoperative pulmonary complications (PPCs), has shown excellent predictive performance in general surgery. However, there is no reliable classification instrument for PPCs prediciton in thoracic surgery. OBJECTIVE: This study aimed to develop and validate a novel nomogram for estimating the risk of pulmonary complications in older patients (≥ 65 years) within 30 days after NCTS. METHODS: A nomogram was developed using predefined candidate predictors of 30-day PPCs. It was fitted with least absolute shrinkage and selection operator and logistic regression methods. Internal validation was performed using a bootstrap-resampling approach, while external validation used an independent, temporally separated cohort. The model's performance was assessed based on its discriminative potential (area under the receiver operating characteristic curve [AUC]), predictive ability (calibration plots), and clinical utility (net benefit). RESULTS: /FVC%, respiratory infection in the last 30 days, and neoadjuvant chemotherapy). The nomogram showed excellent discrimination (AUC = 0.866, 95% confidence interval [CI], 0.846-0.885), calibration (Hosmer- Lemeshow test, P = 0.97) and overall performance (Brier score = 0.014) in the development cohort. Similar results were observed in the external validation cohort (AUC = 0.825, 95% CI, 0.786-0.864). A decision curve analysis indicated that the nomogram offers a positive net benefit compared with the ARISCAT and LAS VEGAS scores. CONCLUSIONS: This novel nomogram can reliably identify older patients with a high risk for pulmonary complications within 30 days after NCTS. TRIAL REGISTRATION: ChiCTR2100051170.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: